RedHill Biopharma (NASDAQ: RDHL; TASE: RDHL) is an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary formulations and combinations of existing drugs.

The company’'s current product pipeline includes: RHB-101 - a once-daily formulation of carvedilol, for the treatment of congestive heart failure and high blood pressure; RHB-102 - A once-daily formulation of ondansetron, for the treatment of chemotherapy and radiotherapy-induced nausea and vomiting; RHB-103 - an oral thin film formulation of rizatriptan, for the treatment of acute migraine; RHB-104 - a combination therapy for the treatment of Crohn'’s disease, multiple sclerosis (MS), and rheumatoid arthritis; RHB-105 - a combination therapy for Helicobacter pylori infection; and RHB-106 - an encapsulated formulation for bowel preparation (laxative) ahead of colonoscopy and other GI procedures.